IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering.

During the stabilization window, Goldman Sachs (Asia) L.L.C., acting as Stabilizing Manager, executed two principal actions:

1. Over-allocations: 6.30 million H shares—equivalent to approximately 15% of the original Global Offering size—were over-allocated in the International Offering. 2. Over-allotment Option: On 5 June 2026, the Overall Coordinators fully exercised the over-allotment option for the same 6.30 million H shares at an offer price of HK$20.10 per share (before brokerage, SFC levy, Stock Exchange trading fee and AFRC levy). These shares were used to settle delayed delivery commitments with placees.

No on-market purchases or sales were conducted for price-stabilization purposes throughout the period.

Following the full exercise of the over-allotment option, IMPACT Therapeutics confirmed that its public float remains in compliance with Listing Rule 19A.28B(1).